To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
GlycoFlux™ human GYS2 overexpression Jurkat cell line is a stable cell line engineered to express glycogen synthase 2 (GYS2), the liver isoform catalyzing the rate-limiting step of glycogen synthesis by transferring glucose from UDP-glucose to glycogen chains. Mutations result in glycogen storage disease type 0. This model offers opportunities to investigate hepatic-type glycogen regulation and its glycosylation-linked modulation in immune cells.
Product Type
Overexpression Cell Lines
Species
Human
Cell Morphology
Suspension-growing
Passage Ratio
1:3~1:5
Cell Line
Jurkat cell line
Primary Disease
T-cell acute lymphoblastic leukemia (T-ALL)
Lineage
T Lymphocyte
Lineage Subtype
T-cell acute lymphoblastic leukemia (T-ALL)
Specification
Cell Viability
>90%
Sterility Test
The sterility test indicated an absence of microbial growth.
Identity Test
STR identification
Mycoplasma Test
Negative
Virus Test
Negative for HIV, HBV and HCV.
Genetic Stability Testing
We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation
qPCR, Sanger Sequencing
Culture Medium
FBS & Penicillin/Streptomycin & RPMI
Application
Mechanistic studies; Exploration of glycosylation and signaling pathways in cancer, metabolic, and immune-related diseases; Drug target validation and other functional assays.
Size
1 M cells/vial*2
Product Format
Frozen
Shipping
Dry ice
Availability Status
Made to order
Handling Notes
Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer
This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.
The protein encoded by this gene, liver glycogen synthase, catalyzes the rate-limiting step in the synthesis of glycogen - the transfer of a glucose molecule from UDP-glucose to a terminal branch of the glycogen molecule. Mutations in this gene cause glycogen storage disease type 0 (GSD-0) - a rare type of early childhood fasting hypoglycemia with decreased liver glycogen content.